<DOC>
	<DOCNO>NCT01906580</DOCNO>
	<brief_summary>Currently , seven medication approve treatment hepatitis B : two formulation interferon five nucleon ( ) ide analogue . The current treatment strategy chronic hepatitis B standard : initial selection entecavir , tenofovir , peginterferon alfa-2a ( peg-IFNα-2a ) . Interferon administer finite duration nucleotide analogue usually administer many year . But among hepatitis B e antigen （HBeAg） positive patient high serum hepatitis B virus DNA level , rate virological response poor . And antiviral drug resistance major limit factor success nucleotide analogue treatment . Therefore , combination therapy use peginterferon oral agent high genetic barrier resistance might superior standard current monotherapy . However , addition lamivudine peg-IFNα-2a therapy lead great decrease serum HBV DNA level treatment increase rate HBeAg sero¬conversion . Entecavir nucleoside analogue superior lamivudine adefovir achieve high virological response , histological improvement normalisation ALT . Moreover , Entecavir high genetic barrier low incidence drug resistance . This study aim investigate efficacy combination sequential therapy use peg-IFNα-2a entecavir HBeAg-positive chronic hepatitis B ( CHB ) patient .</brief_summary>
	<brief_title>Combination Sequential Therapy Peginterferon Alfa-2a Entecavir Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Age≥16 year 2 . HBsAg positive 6 month , HBeAg detection positive two time 6 month enrollment 3 . Serum HBVDNA ＞2×10^4IU/ml 4 . 80U/L &lt; serum ALT &lt; 400U/L , TBIL &lt; 34 umol/L 5 . Serum ALT &lt; 80U/L , hepatic inflammation score ≥ G2 hepatic fibrosis stage ≥ S3 1 . Coinfected HCV , HDV HIV , autoimmune liver disease combine 2 . Hepatic decompensation 3. receive antiviral therapy immunosuppressant drug 6 month prior enrollment 4 . Blood routine examination : WBC ＜3×10^9/L，neutrophile granulocyte ＜ 1.5×10^9/L，PLT ＜80×10^9/L 5 . Renal function : creatinine ＞1.5 time upper normal limit 6 . Alcoholism history addiction abuse 7 . Combined hepatocarcinoma</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HBV</keyword>
	<keyword>entecavir</keyword>
	<keyword>peginterferon</keyword>
</DOC>